This trial is evaluating whether BioXclude™ will improve 3 primary outcomes in patients with Pyorrhea Alveolaris. Measurement will happen over the course of 9 months.
This trial requires 250 total participants across 2 different treatment groups
This trial involves 2 different treatments. BioXclude™ is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
This group of patients had a predisposition to pyuria, a combination of factors and a higher chance of acquiring genital infection with chlamydia or mycoplasm. The lack of adherence to a course of antifungal antibiotic therapy or chronic use of diuretics may be at least partially responsible for the persistence of pyuria.
These signs are typically found in women with an underlying inflammatory cause of the pericoronitis, such as an underlying systemic disease or a history of rheumatic disease. The differential diagnosis should include tuberculosis or dental diseases.
Pyrexia alveolaris is a very rare, chronic, chronic, severe, chronic recurrent form of pyrexia. It is generally difficult to adequately treat by conventional medicines. Patients with severe pyrexia in the absence of other diagnoses or coexisting illnesses are often misdiagnosed as suffering from tuberculosis. These patients receive a lengthy regimen of treatment in addition to the usual antituberculosis treatment, including many oral/ointestinal corticosteroids/sodium cromoglycate/spironolactone. With proper diagnostic approaches and treatment strategies, pyrexia alveolaris can be effectively managed.
Many patients with pyorrhea alveolaris require treatment. The treatment of choice depends on the degree and extent of the disease, and the presence and severity of pain or infection. The most effective treatment is the use of erythromycin, an oral antimicrobicide that belongs to the aminoglycoside group. The use of an oral prokinetic antimicrobicide may help alleviate nausea, vomiting, and diarrhea. Topical products of chlorhexidine may be used as an alternative to oral agents. In severe cases, enemas are effective. Antibiotic therapy is an effective and effective measure to treat infections. Antibiotic therapy should be continued for 2 to 3 months.
About 6.4 million people annually are diagnosed with pyropharyngitis; an equal number of pyropharyngitis cases could be expected. The lifetime risk for developing EPD was 1.0% in this population.
Pyorrhea alveolaris is a disorder which may be the starting point for an infection of the throat, sinus cavity, and rarely the lungs. The most typical sign is fever and pleuritic pain without other findings. The most relevant sign is a pyrexial interval from 5 to 44 hours (average 16 hours). The diagnosis of pyorrhea alveolaris needs to be suspected only when signs disappear without other explanations.
A primary etiology for PA was found and was associated with a positive reaction to the antigen of Streptococcus pneumoniae. This association was confirmed by isolation of S. pneumoniae and by its characterization as the cause of PA in six patients. S. pneumoniae-antigen determination is a simple laboratory test that can be performed on clinical samples to test for bacterial infections and can diagnose the primary cause of PA after a positive reactive result in patients with the clinical syndrome.
The use of Bioxclude™ (miconazole / nystatin) showed similar efficacy as Bifan and Bifan Plus on the cure and resolution of pyrazinamide-sensitive lesions when compared to placebo. It has the benefit of a low rate of side effect and less frequent dosage regimen which reduces the expense and complexity of therapy. It is therefore suitable for use as a second-line monotherapy in tuberculosis.
Bacteremia and perimembranous cellulitis associated with anaerobes and beta-lactamase production in pyogenic arthritis may be a familial phenomenon. The clinical presentation of familial BP is similar to what we have previously reported. Therefore, there is possible inheritance of this condition.
Bioxclude™ was found to be safe and well tolerated in a cohort of people of all ages; no side effects were reported. The study design prohibits definitive conclusion about specific doses in children.
The only published trial that evaluates the efficacy of bioxclude™ on FTM symptoms did not include adequate data to infer definitive efficacy. To date, no additional trials assessing bioxclude™'s use on the treatment of FTM have been reported.
Cortisone treatment was effective and safe for the study population, demonstrating Bioxclude's ability to treat and prevent pyoderma gangrenosum. As demonstrated by high levels of efficacy, cortisone is an effective option in the treatment of pyoderma; however, the development of side-effects may preclude its long-term use. The topical corticosteroid used in this study, bioxclude™, is a steroid-free prescription medication indicated for the treatment of pyoderma gangrenosum. It is a prescription product that is only available to patients who have received full permission from their health plan to use it.